1. Home
  2. EFOR vs CSTL Comparison

EFOR vs CSTL Comparison

Compare EFOR & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Everforth Inc. Common Stock

EFOR

Everforth Inc. Common Stock

N/A

Current Price

$20.74

Market Cap

749.5M

ML Signal

N/A

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$25.09

Market Cap

722.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EFOR
CSTL
Founded
N/A
2007
Country
United States
United States
Employees
2800
N/A
Industry
Professional Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
749.5M
722.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EFOR
CSTL
Price
$20.74
$25.09
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
1.0M
302.5K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
N/A
$2.42
Revenue Next Year
N/A
$12.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.66
52 Week Low
$16.90
$14.59
52 Week High
$21.37
$44.28

Technical Indicators

Market Signals
Indicator
EFOR
CSTL
Relative Strength Index (RSI) 62.65 62.17
Support Level $17.10 $24.89
Resistance Level $21.37 $25.63
Average True Range (ATR) 1.19 1.04
MACD 0.28 0.07
Stochastic Oscillator 90.49 84.83

Price Performance

Historical Comparison
EFOR
CSTL

About EFOR Everforth Inc. Common Stock

Everforth Inc is a technology and digital engineering company that helps organizations adapt, innovate, and thrive in a world of constant change. It has six solution areas: AI & data, cloud and infrastructure, digital engineering, customer experience, cybersecurity, and enterprise platforms - accelerate time to value for commercial and federal clients.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: